Sorry, you need to enable JavaScript to visit this website.

Skip to main content


심장혈관 및 대사 부분 지도력

우리의 재능


심장혈관 및 대사

Cardiovascular & Metabolism

Venous thrombosis
Venous thrombosis

Cardiovascular & Metabolism(CVM)의 Global Therapeutic Area의 Head인 James F. List(M.D., Ph.D.)는 심혈관 및 당뇨병 그리고 질병 차단을 개선하기 위한 새로운 솔루션을 생성하는 데 초점을 맞추고 있는 글로벌 팀을 이끌고 있습니다. Jim은 약물 개발, 임상 개발 그리고 외부 혁신을 포함한 Janssen CVM 포트폴리오에 대한 전체 연구 및 개발 책임을 갖고 있습니다. Jim은 2014년에Janssen에 들어왔습니다.

Janssen에 들어오기 전에 James는 AstraZeneca와의 당뇨병 합작 투자에 대한 책임을 지닌, Diabetes Development 의 Vice President로서 Bristol-Myers Squibb에서 일했습니다.

그의 경력 초기에 James 는 General Endocrinology and Thyroid(일반 내분비학 및 갑상선)에서의 임상 책임을 가진, 메사추세츠주 보스톤의 하바드 메디컬 스쿨의 교수였습니다. 그는 캘리포니아주 스텐포드의 스텐포드 대학을 졸럽하여 미네소타주의 미네아폴리스에 있는 미네소타 대학에서의 의학박사 및 일반박사과정을 완료하였습니다. 그는 모두 메사추세츠 주 보스톤에 있는 Brigham and Women’s Hospital, Boston Children’s Hospital 그리고 the Massachusetts General Hospita에서 그의 의학 트레이닝을 완료하였고 내과, 소아과 및 내분비학에서 위원회 인증을 받았습니다.

James F. List, M.D., Ph.D.

Cardiovascular & Metabolism의 Global Therapeutic Area Head

Calvin Schmidt is Global Commercial Strategy Leader (GCSL) for the Cardiovascular & Metabolism (CVM) therapeutic area and the GCSL for the newly created Johnson & Johnson Innovation World Without Disease Accelerator (WWDA).

CVM is maximizing the value of pipeline and marketed assets and developing innovative solutions for patients, providers and healthcare systems globally by working closely with R&D and BD toward the goal of longer, healthier lives for patients with the world’s most common chronic diseases.

WWDA strengthens Johnson & Johnson’s focus on creating solutions that eliminate disease through early detection, prevention, interception and cure. The WWD Accelerator will identify innovation wherever it originates, internally and externally; leverage relevant capabilities and competencies; build strategic alliances; and seed transformative growth opportunities, by working closely with R&D, BD and Innovation centers across the enterprise.

Prior to this role, he was President of Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, where he led the growth of a business that is making a significant difference for patients suffering from cardiovascular and metabolic diseases. In addition, with extensive international and emerging market experience, Calvin also oversaw the strategic management of Janssen’s portfolio of products in Puerto Rico.

Previously, Calvin was Worldwide Vice President, Human Resources, for the Johnson & Johnson Group of Consumer Companies, a member of the Consumer Group Operating Committee, and a member of the Johnson & Johnson Enterprise Human Resources Executive Committee and served as the first President of Wellness & Prevention, Inc., a Johnson & Johnson company, focused on helping organizations prevent chronic disease and sustain good health for their employees and members.

Other roles at Johnson & Johnson included General Manager, Johnson & Johnson Merck Joint Venture and Global Vice President, Marketing and Sales, for McNeil Nutritionals. Before joining Johnson & Johnson, Calvin was with Mars, Inc. for nearly 15 years, holding domestic and international leadership positions in operations, R&D, product development, marketing and general management.

In September 2017, Calvin was appointed to represent Johnson & Johnson on the Healthcare Leadership Council (HLC), a coalition of top executives from companies representing many sectors in the U.S. health system. In January 2015, he was named to the American Diabetes Association (ADA) Board of Directors, underscoring his dedication to combat the growing epidemic of diabetes; in 2016, he was named Chair of the ADA’s Audit Committee and in 2017 he was also named Chair of the ADA’s CEO search committee.

Calvin holds Master of Business Administration in Marketing and Finance from Capital University in Columbus, Ohio, and a Bachelor of Engineering in Electrical Engineering from Vanderbilt University.

Calvin W. Schmidt

Global Commercial Strategy Leader, Cardiovascular & Metabolism